iBET is a private not for profit research intensive organisation specialized in biotechnology research and bioprocess development. iBET provides high quality process development for the manufacturing of all classes of biopharmaceuticals (Gene therapy, Cell Therapy, Vaccines, mABs...). Hosting more than 200 researchers, iBET is fully compromised in a dynamic translational research programme, pursuing excellence in basic, developmental/preclinical and clinical research. Our expertise encompasses the development of complex biopharmaceuticals and novel therapies which include vaccines, recombinant proteins and viral vectors for gene and onco- therapy, stem cells for cell therapy applications; the development of in-vitro cell models and protocols for pre-clinical research and structural biology for assisted drug design. In the area of food and health iBET has a particular interest in the development of green processes enabling the valorization of industrial by-products, water and energy nexus. iBET aims to reduce human suffering by improving the success in drug development and translation and to reduce the ecological impact of industries by developingsustainable green processes. iBET has been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable impact internationally and has several well established collaborations in Networks of Excellence and with international pharmaceutical companies, such as Bayer, Novartis, Merck, Abbvie, Sanofi, Apceth, AstraZeneca, Glaxo-Smith-Kline , Merck & Co., among others.